Brii Biosciences' 2024 Loss Widens

MT Newswires Live
03-24

Brii Biosciences' (HKG:2137) attributable loss widened to 508.2 million yuan in 2024 from 174.8 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.

Loss per share at the drug company widened to 0.70 yuan from 0.24 yuan in the previous year.

The company did not recognize revenue during the year. In the year-ago period, revenue was 617,000 yuan.

Other income fell to 141.4 million yuan from 163.7 million yuan a year earlier.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10